The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human study of MM-141: A novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3.
Steven J. Isakoff
Consultant or Advisory Role - Merrimack Pharmaceuticals (U)
Mansoor N. Saleh
No relevant relationships to disclose
Alexey Lugovskoy
Employment or Leadership Position - Merrimack Pharmaceuticals
Stock Ownership - Merrimack Pharmaceuticals
Sara Manoli
Employment or Leadership Position - Merrimack Pharmaceuticals
Stock Ownership - Merrimack Pharmaceuticals
Akos Gabor Czibere
Employment or Leadership Position - Merrimack Pharmaceuticals
Stock Ownership - Merrimack Pharmaceuticals
Patricia LoRusso
No relevant relationships to disclose
Monica Arnedos
Consultant or Advisory Role - Merrimack Pharmaceuticals (U)
Honoraria - Novartis